 |
Top 119 Drug Discovery startups
Nov 26, 2024 | By Jason Kwon | 22 |
These startups use AI to accelerate the discovery and development of new drugs.
1
Country: USA | Funding: $5.5M
Converge Bio integrates Generative AI with biological data.
Converge Bio integrates Generative AI with biological data.
2
Country: USA | Funding: $359.9M
Enveda Biosciences is a biotechnology company engineering new drugs from plants.
Enveda Biosciences is a biotechnology company engineering new drugs from plants.
3
Country: USA | Funding: $1.4B
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
4
Country: USA | Funding: $200M
Terray Therapeutics is a biotechnology company that propels drug discovery into the information age.
Terray Therapeutics is a biotechnology company that propels drug discovery into the information age.
5
Country: USA | Funding: $865.4M
Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
6
Country: USA | Funding: $153M
Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development.
Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development.
7
Country: Switzerland | Funding: $2.5B
Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. It is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas.
Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. It is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas.
8
Country: USA | Funding: $1.3B
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.
9
Country: USA | Funding: $1B
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.
10
Country: USA | Funding: $899.9M
Arrowhead Research is focused on developing, commercializing, and licensing a range of nanotechnology products and applications.
Arrowhead Research is focused on developing, commercializing, and licensing a range of nanotechnology products and applications.
11
Country: USA | Funding: $772M
Eikon is pioneering a new method of drug discovery based on tracking and measuring the movement of individual proteins in living cells.
Eikon is pioneering a new method of drug discovery based on tracking and measuring the movement of individual proteins in living cells.
12
Country: USA | Funding: $743M
Insitro is a machine-learning driven drug discovery and development company.
Insitro is a machine-learning driven drug discovery and development company.
13
Country: USA | Funding: $694.1M
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity.
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity.
14
Country: USA | Funding: $693M
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
15
Country: USA | Funding: $546.1M
Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.
Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.
16
Country: USA | Funding: $530.3M
FogPharma creates a new class of medicines that target human disease drivers currently considered undruggable.
FogPharma creates a new class of medicines that target human disease drivers currently considered undruggable.
17
Country: USA | Funding: $487M
Odyssey Therapeutics is a computational immunology company that develops novel therapeutics for patients with autoimmune diseases.
Odyssey Therapeutics is a computational immunology company that develops novel therapeutics for patients with autoimmune diseases.
18
Country: UK | Funding: $474.4M
Exscientia is applying AI and big data processing to accelerate drug discovery and development.
Exscientia is applying AI and big data processing to accelerate drug discovery and development.
19
Country: USA | Funding: $460M
Valo Health is a biotech company that is recreating the future of medicine. Valo is using computers to accelerate drug development while reducing the failure rate
Valo Health is a biotech company that is recreating the future of medicine. Valo is using computers to accelerate drug development while reducing the failure rate
20
Country: USA | Funding: $433.5M
Dicerna Pharmaceuticals develops therapeutic agents in various disease areas based on dicer substrate technology platform. The company offers RNA interference (RNAi)-targeted drugs and delivery systems for therapeutic areas of oncology and metabolic diseases. It also provides Dicer Substrate Technology, a second generation of gene silencing, which triggers RNAi and is used in therapeutic areas, including inflammation, immunology, and cardiovascular diseases.
Dicerna Pharmaceuticals develops therapeutic agents in various disease areas based on dicer substrate technology platform. The company offers RNA interference (RNAi)-targeted drugs and delivery systems for therapeutic areas of oncology and metabolic diseases. It also provides Dicer Substrate Technology, a second generation of gene silencing, which triggers RNAi and is used in therapeutic areas, including inflammation, immunology, and cardiovascular diseases.
